Eli Lilly will acquire AtaiBeckley for $2.8 billion to expand its portfolio of psychedelic mental health treatments.
Eli Lilly will acquire AtaiBeckley for $2.8 billion in upfront cash, a move that provides the pharmaceutical giant with access to experimental psychedelic drugs for mental health conditions. The deal, which offers a 26% premium over AtaiBeckley's recent closing price, includes the potential for an additional $1 billion in payments if specific development and regulatory milestones are met. The acquisition focuses on AtaiBeckley's lead drug, BPL-003, a DMT-based nasal spray currently in Phase 3 clinical trials for treatment-resistant depression. Unlike conventional antidepressants that slowly alter brain chemicals, these psychedelic therapies aim to quickly create new neural connections and restore synaptic connectivity. The move aligns with a broader trend in neuroscience. The administration has prioritized the development of psychedelic-based treatments for conditions such as depression and post-traumatic stress disorder. By securing these assets, Eli Lilly strengthens its position as a leader in psychiatric pharmaceuticals, building on its history of successful mental health medications like Prozac.